LM11A 31 BHS
Alternative Names: LM11A-31; LM11A-31-BHSLatest Information Update: 09 Dec 2025
At a glance
- Originator University of California at San Francisco; University of North Carolina at Chapel Hill
- Developer PharmatrophiX
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Nerve growth factor receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 04 Dec 2025 PharmatrophiX plans a phase II trial for progressive supranuclear palsy (NCT07264283)
- 27 Jul 2025 Pharmacodynamics data from a preclinical study in Alzheimer's disease presented at the Alzheimer's Association International Conference 2025 (AAIC-2025)
- 27 Jul 2025 Pharmacodynamics data from a preclinical study in Alzheimer's disease presented at the Alzheimer's Association International Conference 2025 (AAIC-2025)